Accelerate Diagnostics Company Profile (NASDAQ:AXDX)

About Accelerate Diagnostics (NASDAQ:AXDX)

Accelerate Diagnostics logoAccelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AXDX
  • CUSIP: N/A
  • Web: www.acceleratediagnostics.com
Capitalization:
  • Market Cap: $1.25526 billion
  • Outstanding Shares: 55,298,000
Average Prices:
  • 50 Day Moving Avg: $23.16
  • 200 Day Moving Avg: $25.67
  • 52 Week Range: $19.20 - $30.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -23.89
  • P/E Growth: -0.64
Sales & Book Value:
  • Annual Revenue: $1.29 million
  • Price / Sales: 973.07
  • Book Value: $2.57 per share
  • Price / Book: 8.83
Profitability:
  • EBIDTA: ($61,920,000.00)
  • Net Margins: -5,062.48%
  • Return on Equity: -67.44%
  • Return on Assets: -63.75%
Debt:
  • Current Ratio: 23.03%
  • Quick Ratio: 22.11%
Misc:
  • Average Volume: 320,306 shs.
  • Beta: 2.03
  • Short Ratio: 50.04
 

Frequently Asked Questions for Accelerate Diagnostics (NASDAQ:AXDX)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.40 million. Accelerate Diagnostics had a negative net margin of 5,062.48% and a negative return on equity of 67.44%. View Accelerate Diagnostics' Earnings History.

When will Accelerate Diagnostics make its next earnings announcement?

Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Accelerate Diagnostics.

Where is Accelerate Diagnostics' stock going? Where will Accelerate Diagnostics' stock price be in 2017?

2 brokers have issued 1 year target prices for Accelerate Diagnostics' stock. Their forecasts range from $32.00 to $34.00. On average, they anticipate Accelerate Diagnostics' share price to reach $33.00 in the next year. View Analyst Ratings for Accelerate Diagnostics.

Who are some of Accelerate Diagnostics' key competitors?

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:

  • John Patience, Independent Chairman of the Board
  • Lawrence Mehren, President, Chief Executive Officer, Director
  • Steve Reichling, Chief Financial Officer
  • Joan Martin, Executive Vice President & Head of Europe, Middle East, and Africa
  • Ron Price, Senior Vice President and Head of Commercial Operations, Americas
  • Tom Brown, Independent Director
  • Mark C. Miller, Independent Director
  • Jack W. Schuler, Independent Director
  • Matthew W. Strobeck Ph.D., Independent Director
  • Frank J M ten Brink, Independent Director

Who owns Accelerate Diagnostics stock?

Accelerate Diagnostics' stock is owned by many different of institutional and retail investors. Top institutional investors include Birchview Capital LP (4.20%), Vanguard Group Inc. (2.38%), Cannell Peter B & Co. Inc. (2.11%), Blair William & Co. IL (1.51%), State Street Corp (0.86%) and FMR LLC (0.81%). Company insiders that own Accelerate Diagnostics stock include Brink Frank Jm Ten, Jack W Schuler, Larry N Feinberg, Lawrence Mehren, Matthew Strobeck and Steven Reichling. View Institutional Ownership Trends for Accelerate Diagnostics.

Who sold Accelerate Diagnostics stock? Who is selling Accelerate Diagnostics stock?

Accelerate Diagnostics' stock was sold by a variety of institutional investors in the last quarter, including Trellus Management Company LLC, HighTower Advisors LLC and Neuberger Berman Group LLC. Company insiders that have sold Accelerate Diagnostics stock in the last year include Lawrence Mehren and Steven Reichling. View Insider Buying and Selling for Accelerate Diagnostics.

Who bought Accelerate Diagnostics stock? Who is buying Accelerate Diagnostics stock?

Accelerate Diagnostics' stock was bought by a variety of institutional investors in the last quarter, including AXA, Russell Investments Group Ltd., Artal Group S.A., Kornitzer Capital Management Inc. KS, Oaktop Capital Management II L.P., NGAM Advisors L.P., FMR LLC and Nicholas Investment Partners LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Brink Frank Jm Ten, Jack W Schuler, Larry N Feinberg and Matthew Strobeck. View Insider Buying and Selling for Accelerate Diagnostics.

How do I buy Accelerate Diagnostics stock?

Shares of Accelerate Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of Accelerate Diagnostics stock can currently be purchased for approximately $22.70.


MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Accelerate Diagnostics (NASDAQ:AXDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $33.00 (45.37% upside)

Analysts' Ratings History for Accelerate Diagnostics (NASDAQ:AXDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/12/2017BTIG ResearchReiterated RatingBuy -> Buy$34.00HighView Rating Details
6/5/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00 -> $32.00LowView Rating Details
8/9/2016J P Morgan Chase & CoBoost Price TargetOverweight$17.00 -> $25.00N/AView Rating Details
1/29/2016William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Accelerate Diagnostics (NASDAQ:AXDX)
Earnings by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Earnings History by Quarter for Accelerate Diagnostics (NASDAQ AXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.32)N/AView Earnings Details
8/3/2017Q2 2017($0.30)($0.31)$1.40 million$0.70 millionViewListenView Earnings Details
5/5/2017Q1($0.34)($0.27)$0.60 million$0.50 millionViewListenView Earnings Details
2/27/2017Q4 2016($0.35)($0.31)$0.24 million$0.04 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.35)($0.34)$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Accelerate Diagnostics (NASDAQ:AXDX)
2017 EPS Consensus Estimate: ($1.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.34)($0.34)($0.34)
Q2 20171($0.34)($0.34)($0.34)
Q3 20171($0.31)($0.31)($0.31)
Q4 20171($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Accelerate Diagnostics (NASDAQ:AXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Accelerate Diagnostics (NASDAQ:AXDX)
Insider Ownership Percentage: 51.40%
Institutional Ownership Percentage: 44.43%
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Jack W SchulerDirectorBuy50,000$21.45$1,072,500.00View SEC Filing  
8/17/2017Lawrence MehrenInsiderSell223,215$22.40$5,000,016.00View SEC Filing  
8/15/2017Jack W SchulerDirectorBuy8,200$21.35$175,070.00View SEC Filing  
8/14/2017Jack W SchulerDirectorBuy23,400$21.35$499,590.00View SEC Filing  
8/11/2017Jack W SchulerDirectorBuy80,000$21.43$1,714,400.00View SEC Filing  
6/21/2017Steven ReichlingInsiderSell30,000$28.90$867,000.00View SEC Filing  
1/9/2017Lawrence MehrenInsiderSell400,068$19.00$7,601,292.00View SEC Filing  
1/9/2017Matthew StrobeckDirectorBuy8,000$19.00$152,000.00View SEC Filing  
6/30/2016Jack W SchulerDirectorBuy90,147$13.95$1,257,550.65View SEC Filing  
6/14/2016Jack W SchulerDirectorBuy14,033$13.67$191,831.11View SEC Filing  
6/13/2016Jack W SchulerDirectorBuy15,967$13.70$218,747.90View SEC Filing  
6/10/2016Jack W SchulerDirectorBuy88,316$14.69$1,297,362.04View SEC Filing  
6/9/2016Jack W SchulerDirectorBuy101,272$14.14$1,431,986.08View SEC Filing  
5/20/2016Jack W SchulerDirectorBuy4,270$11.04$47,140.80View SEC Filing  
5/17/2016Jack W SchulerDirectorBuy10,000$11.45$114,500.00View SEC Filing  
5/16/2016Jack W SchulerDirectorBuy11,511$11.91$137,096.01View SEC Filing  
5/13/2016Jack W SchulerDirectorBuy20,000$12.45$249,000.00View SEC Filing  
2/9/2016Jack W SchulerDirectorBuy600,000$11.86$7,116,000.00View SEC Filing  
2/8/2016Jack W SchulerDirectorBuy20,000$12.32$246,400.00View SEC Filing  
2/5/2016Jack W SchulerDirectorBuy7,308$12.65$92,446.20View SEC Filing  
2/4/2016Jack W SchulerDirectorBuy10,000$12.98$129,800.00View SEC Filing  
2/3/2016Jack W SchulerDirectorBuy50,100$13.09$655,809.00View SEC Filing  
2/2/2016Jack W SchulerDirectorBuy20,000$13.46$269,200.00View SEC Filing  
1/21/2016Jack W SchulerDirectorBuy10,000$15.02$150,200.00View SEC Filing  
12/10/2015Larry N FeinbergMajor ShareholderBuy117,647$17.00$1,999,999.00View SEC Filing  
11/5/2015Jack W SchulerDirectorBuy11,899$16.81$200,022.19View SEC Filing  
11/4/2015Jack W SchulerDirectorBuy52,837$16.81$888,189.97View SEC Filing  
10/22/2015Jack W SchulerDirectorBuy2,160$15.82$34,171.20View SEC Filing  
9/29/2015Brink Frank Jm TenDirectorBuy9,800$15.24$149,352.00View SEC Filing  
8/26/2015Jack W SchulerDirectorBuy10,000$17.81$178,100.00View SEC Filing  
8/25/2015Jack W SchulerDirectorBuy10,000$18.56$185,600.00View SEC Filing  
4/17/2015Jack W SchulerDirectorBuy11,000$21.94$241,340.00View SEC Filing  
3/19/2015Matthew StrobeckDirectorBuy2,000$22.04$44,080.00View SEC Filing  
3/9/2015Jack W SchulerDirectorBuy22,584$17.18$387,993.12View SEC Filing  
1/5/2015Jack W SchulerDirectorBuy18,000$18.93$340,740.00View SEC Filing  
9/22/2014Jack W SchulerDirectorBuy2,588$16.44$42,546.72View SEC Filing  
9/19/2014Jack W SchulerDirectorBuy32,411$16.67$540,291.37View SEC Filing  
8/21/2014Jack W SchulerDirectorBuy2,900$16.79$48,691.00View SEC Filing  
8/5/2014Larry N FeinbergMajor ShareholderBuy11,835$15.92$188,413.20View SEC Filing  
8/5/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
8/4/2014Matthew StrobeckDirectorBuy20,000$16.70$334,000.00View SEC Filing  
7/16/2014Larry N FeinbergMajor ShareholderBuy20,000$21.54$430,800.00View SEC Filing  
7/1/2014Jack W SchulerDirectorBuy8,698$25.70$223,538.60View SEC Filing  
6/30/2014Jack W SchulerDirectorBuy10,000$26.09$260,900.00View SEC Filing  
6/30/2014Larry N FeinbergMajor ShareholderBuy20,000$25.72$514,400.00View SEC Filing  
5/12/2014Larry N FeinbergMajor ShareholderBuy297,618$16.80$4,999,982.40View SEC Filing  
2/5/2014Larry N FeinbergMajor ShareholderBuy8,554$24.78$211,968.12View SEC Filing  
1/27/2014Larry N FeinbergMajor ShareholderBuy16,307$13.09$213,458.63View SEC Filing  
12/31/2013Larry N FeinbergMajor ShareholderBuy84,081$12.29$1,033,355.49View SEC Filing  
10/30/2013Larry N FeinbergMajor ShareholderBuy10,000$12.95$129,500.00View SEC Filing  
8/30/2013Larry N FeinbergMajor ShareholderBuy16,001$9.76$156,169.76View SEC Filing  
8/28/2013Larry N FeinbergMajor ShareholderBuy158,445$9.80$1,552,761.00View SEC Filing  
8/16/2013Jack W SchulerDirectorBuy78,494$7.88$618,532.72View SEC Filing  
8/14/2013Jack W SchulerDirectorBuy413,090$8.04$3,321,243.60View SEC Filing  
8/14/2013Larry N FeinbergMajor ShareholderBuy36,814$7.24$266,533.36View SEC Filing  
8/9/2013Larry N FeinbergMajor ShareholderBuy35,168$7.30$256,726.40View SEC Filing  
6/21/2013Larry N FeinbergMajor ShareholderBuy114,250$8.00$914,000.00View SEC Filing  
6/12/2013Larry N FeinbergMajor ShareholderBuy7,175$8.41$60,341.75View SEC Filing  
6/7/2013Larry N FeinbergMajor ShareholderBuy45,508$8.33$379,081.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Accelerate Diagnostics (NASDAQ:AXDX)
Latest Headlines for Accelerate Diagnostics (NASDAQ:AXDX)
Source:
DateHeadline
americanbankingnews.com logoAccelerate Diagnostics (AXDX) and Its Competitors Financial Contrast
www.americanbankingnews.com - September 20 at 2:08 AM
finance.yahoo.com logoETFs with exposure to Accelerate Diagnostics, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 9:17 PM
americanbankingnews.com logoFinancial Contrast: Accelerate Diagnostics (AXDX) and Viveve Medical (VIVE)
www.americanbankingnews.com - September 19 at 4:26 PM
globenewswire.com logoPlaintiffs Dismiss Class Action Appeal Against Accelerate Diagnostics - GlobeNewswire (press release)
globenewswire.com - September 13 at 5:25 PM
feeds.benzinga.com logoPlaintiffs Dismiss Class Action Appeal Against Accelerate Diagnostics
feeds.benzinga.com - September 13 at 1:37 PM
americanbankingnews.com logoBoston Scientific Corporation (BSX) & Accelerate Diagnostics (AXDX) Head to Head Analysis
www.americanbankingnews.com - September 11 at 6:26 PM
americanbankingnews.com logoHead to Head Review: Accelerate Diagnostics (AXDX) versus its Peers
www.americanbankingnews.com - September 10 at 6:06 AM
finance.yahoo.com logoETFs with exposure to Accelerate Diagnostics, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 9:14 PM
nasdaq.com logoCompany Spotlight: Accelerate Diagnostics - Nasdaq
www.nasdaq.com - August 25 at 10:54 PM
finance.yahoo.com logoAccelerate Diagnostics, Inc. :AXDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 4:20 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Purchases 50,000 Shares
www.americanbankingnews.com - August 23 at 1:14 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (AXDX) Insider Sells $5,000,016.00 in Stock
www.americanbankingnews.com - August 18 at 7:26 PM
finance.yahoo.com logoAccelerate Diagnostics (AXDX) In Focus: Stock Rises 5.1%
finance.yahoo.com - August 18 at 4:20 PM
americanbankingnews.com logoJack W. Schuler Acquires 8,200 Shares of Accelerate Diagnostics, Inc. (AXDX) Stock
www.americanbankingnews.com - August 17 at 1:28 PM
americanbankingnews.com logoJack W. Schuler Buys 23,400 Shares of Accelerate Diagnostics, Inc. (AXDX) Stock
www.americanbankingnews.com - August 16 at 1:32 PM
americanbankingnews.com logoInsider Buying: Accelerate Diagnostics, Inc. (AXDX) Director Buys 80,000 Shares of Stock
www.americanbankingnews.com - August 15 at 1:38 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
finance.yahoo.com - August 10 at 2:34 AM
seekingalpha.com logoAccelerate Diagnostics' (AXDX) CEO Lawrence Mehren on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 6 at 8:52 PM
americanbankingnews.com logoAccelerate Diagnostics (AXDX) versus Zeltiq Aesthetics (ZLTQ) Head-To-Head Review
www.americanbankingnews.com - August 5 at 6:30 PM
finance.yahoo.com logoEdited Transcript of AXDX earnings conference call or presentation 3-Aug-17 8:15pm GMT
finance.yahoo.com - August 4 at 9:39 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Announces Earnings Results
www.americanbankingnews.com - August 4 at 4:20 PM
finance.yahoo.com logoAccelerate Diagnostics reports 2Q loss
finance.yahoo.com - August 3 at 10:44 PM
nasdaq.com logoAccelerate Diagnostics Reports Q2 2017 Financial Results, Doubles Revenue Generating Placements - Nasdaq
www.nasdaq.com - August 3 at 5:42 PM
finance.yahoo.com logoAccelerate Diagnostics Reports Q2 2017 Financial Results, Doubles Revenue Generating Placements
finance.yahoo.com - August 3 at 5:41 PM
globenewswire.com logoAccelerate Diagnostics Welcomes Dr. Romney Humphries as Chief ... - GlobeNewswire (press release)
globenewswire.com - July 31 at 4:21 PM
finance.yahoo.com logoAccelerate Diagnostics Welcomes Dr. Romney Humphries as Chief Scientific Officer
finance.yahoo.com - July 31 at 4:21 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (AXDX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:01 AM
finance.yahoo.com logoETFs with exposure to Accelerate Diagnostics, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 3:35 PM
nasdaq.com logoCommit To Purchase Accelerate Diagnostics At $25, Earn 28.8% Annualized Using Options
www.nasdaq.com - July 21 at 5:51 PM
globenewswire.com logoAccelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd - GlobeNewswire (press release)
globenewswire.com - July 18 at 10:47 PM
finance.yahoo.com logoAccelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd
finance.yahoo.com - July 18 at 5:47 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (AXDX) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - July 16 at 4:00 PM
finance.yahoo.com logoETFs with exposure to Accelerate Diagnostics, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 6:08 PM
finance.yahoo.com logoAccelerate Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : AXDX-US : July 12, 2017
finance.yahoo.com - July 12 at 4:50 PM
americanbankingnews.com logoZacks: Accelerate Diagnostics, Inc. (AXDX) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - July 10 at 2:30 PM
marketwatch.com logoWireless Sensing Technologies Energize Oil and Gas Pipeline Monitoring Sector
www.marketwatch.com - July 9 at 4:17 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 4 at 5:56 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (NASDAQ:AXDX) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - July 1 at 7:32 PM
finance.yahoo.com logoBioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
finance.yahoo.com - June 30 at 4:20 PM
finance.yahoo.com logoWalgreens Boots-LabCorp Tie Up for Patient Service Centers
finance.yahoo.com - June 29 at 5:21 PM
nasdaq.com logoQuest Diagnostics to Buy Outreach Lab Service in Cape Cod - Nasdaq
www.nasdaq.com - June 29 at 2:30 AM
finance.yahoo.com logoAccelerate Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : AXDX-US : June 28, 2017
finance.yahoo.com - June 28 at 4:26 PM
zacks.com logoThermo Fisher Gets FDA's PMA for Oncomine Dx Target Test
www.zacks.com - June 27 at 3:54 PM
finance.yahoo.com logo3 Reasons Why Accelerate Diagnostics (AXDX) is a Great Momentum Stock
finance.yahoo.com - June 27 at 3:54 PM
nasdaq.com logoConforMIS (CFMS) Gets FDA Approval for iTotal Hip System - Nasdaq
www.nasdaq.com - June 26 at 4:22 PM
americanbankingnews.com logoAccelerate Diagnostics, Inc. (AXDX) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 23 at 11:28 PM
nasdaq.com logoWhy Investors Should Buy Align Technology (ALGN) Right Now - Nasdaq
www.nasdaq.com - June 23 at 9:25 PM
americanbankingnews.com logoInsider Selling: Accelerate Diagnostics, Inc. (AXDX) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - June 23 at 7:15 PM
americanbankingnews.com logoZacks: Accelerate Diagnostics, Inc. (AXDX) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - June 23 at 11:27 AM
zacks.com logoLantheus (LNTH) Scores a Strong Buy Right Now: Here's How
www.zacks.com - June 22 at 8:55 PM

Social

Chart

Accelerate Diagnostics (AXDX) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff